These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19343228)

  • 1. Prasugrel for arterial coronary thrombosis.
    Serebruany V; Makarov L
    Drugs Today (Barc); 2009 Feb; 45(2):83-91. PubMed ID: 19343228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prasugrel development - claims and achievements.
    Serebruany V; Shalito I; Kopyleva O
    Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of prasugrel, a novel thienopyridine.
    Angiolillo DJ; Bates ER; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S16-22. PubMed ID: 18657682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
    Abbate R; Crea F; De Servi S; Filippi E; Gensini GF; Golinos P; Savonitto S
    G Ital Cardiol (Rome); 2010 Feb; 11(2):127-37. PubMed ID: 20408476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Methods Mol Biol; 2010; 663():221-8. PubMed ID: 20617420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
    Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
    Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prasugrel, a new thienopyridine].
    Schrör K; Huber K
    Hamostaseologie; 2007 Dec; 27(5):351-5. PubMed ID: 18060245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel: a novel antiplatelet agent.
    Riley AB; Tafreshi MJ; Haber SL
    Am J Health Syst Pharm; 2008 Jun; 65(11):1019-28. PubMed ID: 18499874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
    Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
    Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel.
    Tantry US; Bliden KP; Gurbel PA
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1627-33. PubMed ID: 17107286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
    Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Medication of the month. Prasugrel (Efient): potent thienopyridine antiplatelet agent].
    Lancellotti P
    Rev Med Liege; 2010 Nov; 65(11):642-7. PubMed ID: 21189531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.
    Angiolillo DJ; Suryadevara S; Capranzano P; Bass TA
    Expert Opin Pharmacother; 2008 Nov; 9(16):2893-900. PubMed ID: 18937620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.